May 22, 2020 8:51am EDT Nexera Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment
May 07, 2020 5:00pm EDT Nexera Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan
Apr 08, 2020 8:30am EDT Nexera Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
Feb 28, 2020 8:59am EST Nexera Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Feb 18, 2020 6:52pm EST Nexera Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020
Nov 29, 2019 5:00pm EST Nexera Pharmaceuticals Reports Operating and Financial Results for the Second Quarter of Fiscal 2020
